The nation of Zimbabwe has turned down a substantial US health deal worth $367m (£272m) over five years over Washington's request for confidential information.
This rejection became public following a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official representative later explained that the United States was requesting health data for scientific study and commercial purposes but was not willing to share the benefits from future treatments.
"We are forced to start the difficult and regrettable task of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged more talks to reach a agreement agreeable to both sides so the country's vital HIV programme can proceed.
Broader Implications
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a similar health funding agreement following legal challenges were raised about the safety of citizens' health data.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was seeking direct bilateral deals to boost openness and responsibility.
As per reports, Sixteen nations in Africa have so far agreed to similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment via American-funded initiatives," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that provided information," his statement read.
"In essence, our nation would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be available to our people should a future disease outbreak arise."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one health agreements were upending structures previously set up through the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This system is intended to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how future co-operation might be designed in a manner that respects the independence and dignity of each country."
Medical Community Reaction
Medical experts stated it recognised the official position, but urged that talks must proceed since much of the country's HIV programmes depended on international support.
"In cases where specific concerns exist, such as those involving information security or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," the group commented.
The halted deal underscores the continuing challenges between accepting crucial international aid and safeguarding a country's data in an increasingly interconnected world.